Drug Profile
Research programme: gastrointestinal disorders and cystic fibrosis therapeutics - Adare Pharmaceuticals/NuMedii
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aptalis; NuMedii
- Developer NuMedii
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis; Gastrointestinal disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cystic-fibrosis in USA
- 16 Jul 2016 No recent reports of development identified for research development in Gastrointestinal-disorders in USA
- 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals